首页> 外文期刊>Tissue engineering, Part A >Reconstruction of functional ocular surface by acellular porcine cornea matrix scaffold and limbal stem cells derived from human embryonic stem cells
【24h】

Reconstruction of functional ocular surface by acellular porcine cornea matrix scaffold and limbal stem cells derived from human embryonic stem cells

机译:脱细胞猪角膜基质支架和人胚胎干细胞衍生的角膜缘干细胞重建功能性眼表

获取原文
获取原文并翻译 | 示例
       

摘要

Limbal stem cells (LSCs) derived from human embryonic stem cells (hESCs) hold great potential for cell-based therapies for ocular surface diseases. The cell-based therapies mainly depend on an appropriate differentiation proposal with a high efficiency and on a suitable scaffold. In this study, we aimed to establish a feasible and efficient strategy for inducing hESCs into LSC-like cells by the LSC conditioned medium. The induced cells possessed the similar morphologic characteristics and expression of normal LSCs and showed a strong clonogenic and proliferative capacity in vitro. To construct a tissue-engineering corneal graft, these differentiated cells were seeded on an acelluar porcine corneal matrix (APCM), which maintained the corneal basement membrane in vitro. After 14 days culture, these induced cells gave rise to stratified epithelial cell sheets on the APCM and the basal cells still kept LSC characteristics. In rabbit total limbal stem cell deficiency (LSCD) models, the tissue-engineering graft had the potential to reconstruct the damaged ocular surface and alleviated the invasion of corneal neovascularization. These findings indicated that the engraftment constructed with the APCM scaffold and hESC-derived LSCs might be a potential therapy option for ocular surface regeneration in LSCD cases.
机译:源自人类胚胎干细胞(hESC)的边缘干细胞(LSC)在基于细胞的眼表疾病治疗中具有巨大潜力。基于细胞的疗法主要取决于高效的合适分化方案和合适的支架。在这项研究中,我们旨在建立一种可行且有效的策略,通过LSC条件培养基将hESCs诱导入LSC样细胞。诱导的细胞具有相似的形态特征和正常LSCs的表达,并在体外显示出很强的克隆形成和增殖能力。为了构建组织工程性角膜移植物,将这些分化的细胞接种到猪角膜基质细胞(APCM)上,该基质在体外维持角膜基底膜。培养14天后,这些诱导的细胞在APCM上产生分层的上皮细胞片,并且基底细胞仍然保持LSC特性。在兔全角膜缘干细胞缺乏症(LSCD)模型中,组织工程移植物具有重建受损眼表并减轻角膜新生血管入侵的潜力。这些发现表明,用APCM支架和hESC衍生的LSC构建的植入物可能是LSCD病例眼表再生的潜在治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号